P1.058. Angiotensin System Inhibitors and Outcomes After Neoadjuvant Therapy for Locally Advanced ESCC

Clicks: 21
ID: 325986
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #143 of 453 articles by views in diseases of the esophagus : official journal of the international society for diseases of the esophagus

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 453 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Topic Esophageal Cancer: Adjuvant and Neo-Adjuvant Therapies Background Renin angiotensin system signaling has been implicated in tumor growth, angiogenesis, immune modulation, and responses to cytotoxic and radiation-based therapies, yet clinical effects appear heterogeneous across tumor histologies and treatment contexts.Angiotensin system inhibitors (ASIs) are widely used for cardiovascular indications and represent a plausible, readily implementable adjunct if associated with improved oncologic outcomes. We evaluated the prognostic impact of peritreatment ASI use in patients with locally advanced esophageal squamous cell carcinoma (ESCC) treated with neoadjuvant therapy followed by curative esophagectomy. Methods We retrospectively reviewed a multicenter database of consecutive patients with locally advanced ESCC who received neoadjuvant chemotherapy (nCT) or neoadjuvant chemoradiotherapy (nCRT) followed by radical esophagectomy. ASI exposure was prospectively documented. Overall survival (OS) and disease-free survival (DFS) estimated with Kaplan-Meier methods and compared using multivariable Cox regression. Prespecified subgroup analyses were performed by neoadjuvant regimen. A causal mediation analysis decomposed the association between ASI and OS into direct and indirect effects. Results Among 580 patients, 40 (6.9%) used ASIs, 275 (47.4%) received nCT and 305 (52.6%) received nCRT. Neoadjuvant regimen was not associated with OS (p=0.745) or DFS (p=0.358). Overall, ASI use was not significantly associated with OS (p=0.199) or DFS (p=0.642). In the nCT subgroup, ASI use was associated with improved DFS (HR=0.364; p=0.047) and borderline improved OS (HR=0.264; p=0.063), whereas no benefit was observed in the nCRT cohort (p=0.899 for OS; p= 0.109 for DFS). Mediation analysis showed significant indirect effects via DFS in the overall cohort (HR=0.629; p=0.004) and nCT subgroup (HR=0.264; p<0.001), with non-significant direct effects. Conclusion ASI use may be associated with improved outcomes in ESCC patients treated with neoadjuvant chemotherapy, with benefits appearing to operate primarily through reduced recurrence rather than a direct survival effect. No advantage was observed among patients receiving chemoradiotherapy. Given the small exposed proportion and retrospective design, these findings warrant prospective validation and mechanistic studies to clarify treatment-interaction effects and to identify patient subgroups most likely to benefit.
Reference Key
openalex_W7203970383 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Su Feng, Subinuer Maimaiti, Xu Huang, Jun Yin, Yaxing Shen
Are you one of these authors? Claim your profile
Journal diseases of the esophagus : official journal of the international society for diseases of the esophagus
Year 2026
DOI
10.1093/dote/doag077.206
URL
https://doi.org/10.1093/dote/doag077.206
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.